Nektar Therapeutics Reportedly Considering Sale

Nektar Therapeutics is exploring options including a potential sale of the $15 billion biotechnology firm, according to people with knowledge of the matter. The San Francisco company could also opt for partnerships and licensing agreements instead of a disposal, said the people, asking not to be identified because the discussions are private. Nektar has attracted interest from larger drugmakers, though some potential suitors are wary of a full takeover because of the high valuation and risks related to its pipeline of experimental drugs, the people said. No final decisions have been made and considerations may not lead to a transaction, they said.

BING NEWS:
  • Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test
    Nektar Therapeutics' rezpegaldesleukin is now in two phase 2 studies, one in atopic dermatitis and one in alopecia areata. The phase 1b data in atopic dermatitis show promise, and a 400-patient ...
    04/9/2024 - 6:30 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News